[Expert consensus on the management of breast cancer antibody-drug conjugates infusion].

Antibody-drug conjugates (ADC) are a new class of antineoplastic agents whose structure is composed of a monoclonal antibody covalently attached to a cytotoxic drug via a chemical linker. The introduction and clinical application of ADC change the treatment pattern of human epidermal growth factor receptor 2 (HER2) and triple-negative breast cancer, which is put forward new requirements for the standardized use and management of ADC drugs for medical staff. ADC drugs infusion norms and the prevention and management of adverse reactions are important prerequisites for ensuring drug efficacy and safety. Therefore, the Breast Cancer Case Manager Branch of the Chinese Medical Education Association and the consensus formulation group on targeted drug infusion norms jointly formulated an expert consensus on management of breast cancer antibody-drug conjugates infusion norms. The aim is to provide practical guidance and the early prevention and timely management of related adverse reactions of ADC drugs such as Trastuzumab Emtansine, Trastuzumab Deruxtecan, and Sacituzumab Govitecan for clinical staff.近年来快速发展的抗体偶联药物（ADC）靶向生物制剂，是一类由单克隆抗体经由连接分子与细胞毒类药物偶联结合而组成的新型抗肿瘤药物。新型ADC药物的上新以及在临床上的推广应用，在改变人类表皮生长因子受体2（HER2）阳性以及三阴性乳腺癌的治疗格局的同时，对医护人员ADC药物的规范使用及管理提出新的要求。ADC药物的输注规范、不良反应的预防和管理等是保证药物疗效及安全的重要前提，因此，中国医药教育协会乳腺癌个案管理师分会及靶向药物输注规范共识制定小组共同制定了乳腺癌抗体偶联药物输注管理专家共识，旨在为临床医护人员提供恩美曲妥珠单抗、德曲妥珠单抗、戈沙妥珠单抗等ADC药物的输注规范以及相关不良反应的早期预防和及时管理的实践指导。.